The American Journal of Managed Care18h
Liver Fibrosis Scores May Hint at Heart Failure Risk
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over 15 Companies are Progressing Through to Improve the Treatment Landscape | DelveInsight
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
Aileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary Fibrosis
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
The American Journal of Managed Care1d
Novel, AI-Procured ISM001-055 Demonstrates Great Promise for Treatment of IPF
The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...
FierceBiotech1d
Insilico's AI-designed med tied to respiratory health improvements in midstage lung disease trial
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
BioSpace1d
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...